AOD-9604: Fat Loss Peptide Research & Mechanism
This comprehensive guide examines the latest research on aod-9604 peptide, covering mechanisms of action, published study data, research protocols, and safety considerations. As the field of peptide science continues to advance, understanding the evidence base for specific compounds and applications becomes increasingly important for researchers and investigators.
AOD-9604 peptide research has generated considerable interest in the metabolic research community due to its selective lipolytic properties derived from the fat-reducing region of human growth hormone. As a modified fragment of the HGH molecule (amino acids 176-191 with a tyrosine addition), AOD-9604 was designed to isolate the fat metabolism effects of growth hormone while eliminating the diabetogenic and growth-promoting properties.
Researchers can access high-purity research compounds through Proxiva Labs, with all products verified via our third-party testing program.
HGH Fragment 176-191: Mechanism of Action
AOD-9604 derives from the C-terminal region of human growth hormone, specifically amino acids 176-191 with a tyrosine substitution at position 182. This region was identified as the portion of HGH responsible for its lipolytic (fat-burning) activity.
- Beta-3 adrenergic pathway — AOD-9604 stimulates lipolysis through enhancement of beta-3 adrenergic receptor signaling in adipose tissue
- Hormone-sensitive lipase — The peptide activates hormone-sensitive lipase (HSL), the key enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol
- Anti-lipogenic effect — In addition to promoting fat breakdown, AOD-9604 inhibits lipogenesis (new fat formation), creating a dual effect on fat metabolism
- No IGF-1 stimulation — Unlike full-length HGH, AOD-9604 does not stimulate IGF-1 production, avoiding the growth-promoting and potential diabetogenic effects
- No glucose effects — Research has shown that AOD-9604 does not impair glucose tolerance or insulin sensitivity, a key advantage over exogenous GH administration
Clinical Trial Results
AOD-9604 has undergone clinical evaluation, producing mixed results that inform our understanding of its potential and limitations.
Phase 2 Clinical Data
A phase 2 clinical trial in obese subjects demonstrated dose-dependent weight loss with oral AOD-9604 administration. The 1 mg/day group showed statistically significant weight loss compared to placebo over the 12-week study period. Importantly, the weight loss appeared to preferentially target fat mass while preserving lean body mass.
- Dose-dependent response observed across 0.25, 0.5, and 1.0 mg/day groups
- Preferential fat mass reduction with lean mass preservation
- No significant changes in IGF-1, glucose, or insulin levels
- Well-tolerated with a safety profile comparable to placebo
Phase 3 Outcomes
A subsequent larger phase 3 trial did not achieve its primary efficacy endpoint of statistically significant weight loss versus placebo in the overall study population. This has been attributed to several factors including possible underdosing, the oral bioavailability limitations of the peptide, and the heterogeneity of the study population. Despite the primary endpoint failure, subgroup analyses suggested efficacy in certain patient populations.
Cartilage and Joint Research
An unexpected research direction emerged when AOD-9604 demonstrated chondroprotective properties, leading to investigation as a potential cartilage repair agent.
- Proteoglycan synthesis — AOD-9604 stimulated proteoglycan production in articular chondrocytes, a key component of cartilage matrix
- Anti-inflammatory — The peptide reduced inflammatory markers in joint tissue models
- Intra-articular studies — Direct joint injection of AOD-9604 showed promise in preclinical osteoarthritis models
- TGA listing — In Australia, AOD-9604 received a TGA listing for use as a compounded intra-articular injection for osteoarthritis
Research Protocols and Dosing
Published AOD-9604 research has explored multiple administration routes.
- Subcutaneous — 250-500 mcg per day, typically administered in the morning on an empty stomach for fat loss research
- Oral — 1-5 mg per day (higher dose needed due to lower oral bioavailability)
- Intra-articular — Variable doses for joint injection, typically in the mg range for cartilage research
- Duration — 12-week protocols most common in clinical research; some studies extend to 24 weeks
- Timing — Morning administration on an empty stomach, as food intake may affect absorption
Safety Profile
AOD-9604 has demonstrated a favorable safety profile across clinical studies.
- No hormonal disruption — Does not affect IGF-1, HGH, thyroid hormones, or cortisol levels
- No glucose/insulin impact — Unlike exogenous GH, does not impair glucose tolerance
- WADA status — Listed as a banned substance by WADA for athletic competition
- FDA GRAS status — Received Generally Recognized As Safe designation from the FDA for oral use as a food ingredient
- Mild side effects — Occasional headache and injection site reactions reported in clinical trials at rates comparable to placebo
Key References
- Wilding et al., 2021 — semaglutide STEP trial
- Jastreboff et al., 2022 — tirzepatide SURMOUNT
- Jastreboff et al., 2023 — retatrutide phase 2
Related Research Resources
Explore related topics in our research guide library:
- Semaglutide Weight Loss Results
- Bpc 157 Vs Collagen Peptides
- Semaglutide Vs Metformin
- Bpc 157 Tendon Repair Research
- Browse All Research Guides
Conclusion
AOD-9604 research demonstrates the potential of peptide fragment design to isolate specific biological activities from larger hormone molecules. While clinical outcomes for weight loss have been mixed, the dual lipolytic/anti-lipogenic mechanism, favorable safety profile, and emerging cartilage applications continue to sustain research interest in this modified growth hormone fragment.
Researchers can explore our full catalog of research peptides and access the latest peptide research guides for ongoing updates in this rapidly evolving field.